LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Defective Genome Instability Suppressing Genes May Cause Some Types of Cancer

By LabMedica International staff writers
Posted on 28 Apr 2016
Print article
Image: Drop-inoculation of Saccharomyces cerevisiae mutants on an agar plate. The assay compares the viability of different yeast mutants (Photo courtesy of Wikimedia Commons).
Image: Drop-inoculation of Saccharomyces cerevisiae mutants on an agar plate. The assay compares the viability of different yeast mutants (Photo courtesy of Wikimedia Commons).
Cancer researchers reported in a recent study that defects in the expression of genes that suppress gross chromosomal rearrangements (GCRs) were linked to more than 93% of the ovarian and 66% of the colorectal cancer cases they had examined.

Investigators at the University of California, San Diego (USA) worked with the yeast Saccharomyces cerevisiae to identify genome instability suppressing (GIS) genes that acted to prevent chromosomal rearrangements. They reported in the April 13, 2016, online edition of the journal Nature Communications that by using this platform they had been able to identify182 GIS genes that suppressed GCR formation. Another 438 cooperatively acting GIS genes (cGIS) were identified that were not GIS genes, but suppressed the increased genome instability caused by individual query mutations.

Analysis of data derived from The Cancer Genome Atlas (TCGA) allowed the investigators to predict which human genes were associated with GIS pathways. This analysis revealed that a minimum of 93% of ovarian and 66% of colorectal cancer cases had defects affecting one or more predicted GIS gene. These defects included loss-of-function mutations, copy-number changes associated with reduced expression, and silencing. In contrast, acute myeloid leukemia cases did not appear to have defects affecting the predicted GIS genes.

"Mutated GIS genes have long been suspected of playing a role in the development of many types of cancers, but identifying them has been difficult due in large part to a lack of comprehensive GCR tests, or assays, in mammalian systems," said first author Dr. Christopher Putnam, adjunct assistant professor of medicine at the University of California, San Diego School of Medicine. "Before our experiment, only a few dozen cGIS genes were known. Now we know of hundreds. Understanding this process allows us to think more about how carcinogenesis proceeds and it might give us insights into defects that could be therapeutically actionable in the future."

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more